Clene Inc. (CLNN) |
|
2.65 -0.07 (-2.57%)
|
06-29 18:46 |
|
Open: |
2.71 |
Pre. Close: |
2.72 |
|
High:
|
2.835 |
Low:
|
2.65 |
|
Volume:
|
184,110 |
Market Cap:
|
168(M) |
|
|
|
|
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2/3 registrational clinical trial for patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; ongoing Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a planned Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company's products also include CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to accelerate wound healing; CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease, such as COVID-19 and to provide immune support for symptom resolution; and CNM-PtAu7, a gold-platinum CSN therapeutic for oncology applications. It also markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
2.84 - 2.85 |
2.85 - 2.87 |
|
Low:
|
2.61 - 2.63 |
2.63 - 2.65 |
|
Close:
|
2.62 - 2.65 |
2.65 - 2.67 |
|
Technical analysis |
as of: 2022-06-29 4:52:18 PM |
|
Overall:
|
 |
| Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
| Target: |
Six months: 4.07 One year: 5.06 |
| Support: |
Support1: 2.1 Support2: 1.75 |
| Resistance: |
Resistance1: 3.48 Resistance2: 4.34 |
| Pivot: |
2.85  |
| Moving Average: |
MA(5): 2.82  MA(20): 2.86
MA(100): 2.84 MA(250): 4.85 |
| MACD: |
MACD(12,26): 0 Signal(9): 0 |
| Stochastic oscillator: |
%K(14,3): 26.3 %D(3): 29.3 |
| RSI: |
RSI(14): 48.3 |
| 52-week: |
High: 17.81 Low: 1.92 |
| Average Vol(K): |
3-Month: 270 (K) 10-Days: 811 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ CLNN ] has closed above bottom band by 39.8%. Bollinger Bands are 86.4% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 15 days. This is a sign that the current trend might continue. |
|
|
Headline News |
Mon, 27 Jun 2022
2022-06-27 | NDAQ:CLNN | Press Release | Clene Inc. - Stockhouse
Tue, 21 Jun 2022
Insider Buying: Clene Inc. (NASDAQ:CLNN) Director Buys 74,610 Shares of Stock - MarketBeat
Tue, 21 Jun 2022
David J. Matlin Buys 74610 Shares of Clene Inc. (NASDAQ:CLNN) Stock - Defense World
Thu, 16 Jun 2022
Clene Inc. (NASDAQ:CLNN) Director Alison Mosca Buys 5000 Shares - Defense World
Mon, 13 Jun 2022
Healthcare Stocks on the Move Monday: DAWN, HILS, OPTN, EKSO, CLNN, CRBU, GLS, RVPH - InvestorsObserver
Tue, 07 Jun 2022
Clene Inc. (NASDAQ:CLNN) Director David J. Matlin Acquires 10,000 Shares - MarketBeat
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Neutral |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
0 (M) |
| Shares Float |
62 (M) |
|
% Held by Insiders
|
1.63e+007 (%) |
|
% Held by Institutions
|
67.9 (%) |
|
Shares Short
|
2,960 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
-4.902e+007 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
61.4 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-6 |
|
Return on Assets (ttm)
|
912.5 |
|
Return on Equity (ttm)
|
-47.6 |
|
Qtrly Rev. Growth
|
723000 |
|
Gross Profit (p.s.)
|
5329.09 |
|
Sales Per Share
|
-1368.73 |
|
EBITDA (p.s.)
|
3.94545e+006 |
|
Qtrly Earnings Growth
|
-0.3 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
-35 (M) |
Stock Valuations |
|
PE Ratio
|
-0.01 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0.04 |
|
Price to Sales
|
-0.01 |
|
Price to Cash Flow
|
3.23 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
3.08e+006 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
